Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jan 12;90(1):100-5.
doi: 10.1038/sj.bjc.6601468.

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

W Albrecht  1 , H Van Poppel, S Horenblas, G Mickisch, A Horwich, V Serretta, G Casetta, J M Maréchal, W G Jones, S Kalman, R Sylvester
Affiliations
Clinical Trial

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

W Albrecht et al. Br J Cancer. .

Abstract

Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses were observed. Toxicity was unexpectedly high in both treatment arms and led to treatment withdrawal or refusal in 49% of all patients, predominantly already during the first treatment cycle. The mean treatment duration was 10 and 14 weeks, median time to PSA progression was 27.2 and 30.8 weeks, median survival time was 44 and 50.9 weeks, and PSA response rate was only 24.6 and 28.9% in the EMP/VBL and EMP arms, respectively. There was no correlation between PSA response and survival. While the PSA response in the patients tested was less than half that recorded in the North American studies, the toxicity of EMP monotherapy or in combination with VBL was much higher than expected. Further research on more effective and less toxic treatment strategies for hormone refractory prostate cancer is mandatory.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of treatment.
Figure 2
Figure 2
Time to PSA-progression from nadir.
Figure 3
Figure 3
Duration of survival.
Figure 4
Figure 4
Duration of survival in respect to PSA response.
See this image and copyright information in PMC

References

    1. Amato RJ, Ellerhorst J, Bui C, Logothetis CJ (1995) Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1: 168–172 - PubMed
    1. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E (1999) A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res 5: 2324–2329 - PubMed
    1. Benson RC, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8: 375–380 - PubMed
    1. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461–3467 - PubMed
    1. Crawford ED, Eisenberger MA, McLeod MA, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic cancer. New Engl J Med 321: 419–924 - PubMed

MeSH terms